Journal of Practical Hepatology ›› 2021, Vol. 24 ›› Issue (6): 799-802.doi: 10.3969/j.issn.1672-5069.2021.06.008

• Hepatitis in vitro, in mice and in rats • Previous Articles     Next Articles

Effects of trimetazidine on the expression of NOX2 and NOX4 in liver tissues of mice with acute liver failure

Wang Ya, Luo Tingting, Li Can, et al   

  1. Department of Infectious Diseases, Affiliated Hospital, Guizhou Medical University, Guiyang 550000, Guizhou Province, China
  • Received:2020-11-25 Online:2021-11-10 Published:2021-11-15

Abstract: Objective The aim of this experiment was to investigate the effect of trimetazidine on the expression of NOX2 and NOX4 in liver tissues of mice with D-Galn/LPS-induced acute liver failure (ALF). Methods 65 male C57BL/6 mice were randomly divided into control, model, low-, moderate- and high-dose of trimetazidine, as wells as reduced glutathione-intervened group, 10 in each except for those (n=15) in the model. The ALF model was established by D-Galn/LPS intraperitoneal injection. The liver tissue homogenate malondialdehyde (MDA) and peroxidase (CAT) levels were detected, and hepatic NOX2/4 mRNA levels and protein expression were assayed by RT-PCR and Western blot. Results Serum ALT, AST and hepatic MDA levels in model group were (121.4±3.7)U/L,(208.9±27.4)U/L and (51.0±20.5)nmol/mg, all significantly higher than [(35.3±3.2)U/L, (49.9±4.4)U/L and (14.1±5.2) nmol/mg, P<0.05] in the control, while hepatic CAT level was (51.7±16.8)U/mg, significantly lower than [(110.2±33.7)U/mg, P<0.05] in the control; the hepatic NOX2/4 mRNA level and their protein expression in the model were (8.2±2.0)/(1.2±0.1) and (2.6±0.1)/(1.3±0.1), significantly higher than [(1.0±0.2)/(0.5±0.1) and (1.0±0.1)/(0.4±0.1), P<0.05] in the control, serum ALT, AST and hepatic MDA levels in moderate- and high-dose trimetazidine-intervened groups were (86.4±1.00)U/L, (154.0±6.2)U/L and (22.5±1.9)nmol/mg, as well as (81.1±1.5)U/L, (134.7±5.3)U/L and (20.1±3.7)nmol/mg, significantly lower than [(121.4±3.7)U/L, (208.9±27.4)U/L and (51.0±20.5) nmol/mg, P<0.05] in the model, hepatic CAT level were (99.4±15.5) and (102.3±15.5), significantly higher than [(51.6±16.8), P<0.05] in the model; hepatic NOX2/4 mRNA levels and their protein expression were (5.6±0.2)/(0.7±0.0) and (5.2±1.4/0.6±0.1) as well as (1.7±0.2)/(0.7±0.2) and (1.5±0.1)/(0.6±0.2), significantly lower than [(8.2±2.0)/(1.2±0.1) and (2.6±0.1)/(1.3±0.1), P<0.05] in the model. Conclusion Trimetazidine might inhibit the oxidative stress by down-regulation of hepatic NOX2/4 expression and improve the liver functions in D-Galn/LPS-induced mice.

Key words: Acute liver failure, Trimetazidine, Oxidative stress, NOX2, NOX4, Mice